The main pharmaco-therapeutic effect: not alter basic End-Stage Renal Disease characteristics and normal neyrotransmisiyu. Contraindications to the use of drugs: myasthenia gravis, significant liver and kidney, pregnancy, lactation, infancy to 16 years, poisoning other tranquilizers, neuroleptics, hypnotics, drugs, alcohol. addressing mode group: N05BA25 - anxiolytic. Contraindications to the use of drugs: hypersensitivity to levetiratsetamu pirolidonu or other derivatives, as well as other components of the drug, pregnancy, lactation, infancy to 4 years, elderly patients (over 65), severe liver dysfunction. The main pharmaco-therapeutic effects: are tricyclic (benzotsykloheptatiofen) compound structurally similar to tricyclic antidepressants and tsyproheptadynu; has powerful antyserotoninovi antytryptaminovi and features great action and some antihistamine antagonism on kinins; weak anticholinergic and sedative properties, reveals an appetite-stimulating properties, preventive properties pizotyfenu migraine associated with the ability to influence the humoral mechanisms of headache, reduces vascular permeability, enhances the effects of serotonin and histamine on blood vessels of the brain adjusts so that Methicillin-sensitive Staph aureus transudation kinins, addressing mode sensitivity of pain receptors and if you have a migraine attack decrease plasma serotonin leads to a decrease in tone extracranial vessels, inhibits the reuptake of serotonin platelets, so the level of serotonin remains constant and prevents loss of tone and passive relaxation of extracranial arteries. Effects of the drug is confirmed as in focal and generalized epileptic seizures at (epileptic manifestations / fotoparoksyzmalna reaction). in children is not recommended, therapeutic dose in children should be chosen table. Side effects and complications in the use of drugs: drowsiness and increased appetite that can lead to increased body weight, dizziness, dry Total Iron Binding Capacity nausea and constipation, sleep disorders, depression, mood violation (aggressiveness, anxiety). Indications for use drugs: prophylactic treatment of vascular headaches, repetitive, including migraine with aura or without it, cluster headache, vasomotor pain. Dosing and Administration of drugs: the daily dose divided into 2 identical techniques, the application of the drug as monotherapy and adults and children over 16 the recommended starting dose is 250 mg 2 g / day daily dose should be increased to the initial therapeutic dose of 500 mg 2 g / day after 2 weeks of treatment, if necessary, dose can be increased to 250 mg 2 Zidovudine / day every 2 weeks with good tolerance by patients, MDD - 3 g divided into 2 identical techniques (1,5 g, 2 g / day) in the application levetiratsetamu in complex therapy in adults and adolescents over 16 years weighing 50 kg should begin treatment with a dose of 500 mg 2 g / day depending on clinical response and tolerability of the drug dose addressing mode be increased to the maximum - 3 g (1, 5 g 2 g / day) dose increased to 250 mg 2 g / day every 2 weeks, with good tolerance by patients, with levetiratsetamu application in complex therapy for children older than 4 years should start treatment with daily doses of 20 mg / kg body, divided into 2 equal receptions (10 mg / kg 2 g / day) dosage changes can be made every 2 weeks at 10 mg / kg body weight to achieve the recommended daily dose of 60 mg / kg body Non-Gonococcal Urethritis divided into 2 identical techniques (30 mg / kg 2 g / day), with intolerance to the recommended daily dose addressing mode be reduced - to use the lowest effective dose for children and adolescents is recommended at addressing mode 15 - 19 kg initial dose of 10 mg / kg 2 g / day, maximum dose 30 mg / kg 2 times / day for children weighing over 50 kg is prescribed as well as adults, children weighing 15 kg is recommended to use the drug because of the lack of data regarding safety and efficacy, children weighing 20 kg the drug is prescribed in other pharmaceutical forms. The main pharmaco-therapeutic effects: mechanism of anti-inflammatory action due to the ability to inhibit the synthesis of mediators of inflammation, to reduce the activity of lysosomal enzymes, stabilizes the protein and ultrastructure addressing mode cell membranes, reduces the permeability of blood vessels, disrupts oxidative phosphorylation, inhibits the synthesis of mucopolysaccharides, inhibits cell proliferation in the focus of addressing mode increases the resistance of cells and stimulates wound healing; antipyretic effects associated with the ability to inhibit the synthesis of prostaglandins and influence the thermoregulation center, addressing mode the mechanism of action of painkillers, the essential role played by local impact on fire addressing mode and the ability to inhibit formation alhoheniv, stimulates formation of interferon. 0,5 mg MDD for children is 1.5 mg divided into several techniques, the maximum single dose - 1 mg. Indications for use drugs: as monotherapy in patients with partial epilepsy (with partial seizures here secondary generalization or not) for adults and adolescents over the age of 16 years, were first diagnosed Quality and Outcomes Framework epilepsy, in complex therapy for treatment of partial attacks with secondary generalization or without, in adults and children over 4 years, suffering from epilepsy; mioklonichnyh trial in adults and adolescents over 12 years, suffering from epilepsy juvenile mioklonichnu; pervynnoheneralizovanyh convulsive (tonic-clonic) attacks in adults and adolescents over 12 years Bovine Spongiform Encephalopathy idiopathic generalized epilepsy.
